CNS Innovator Oligonucleotide Licensing Value Surges by 339% to $2.8 Billion in 2024, Reveals GlobalData

CNS innovator oligonucleotide licensing value surges by 339% to $2.8 billion in 2024, reveals GlobalData - Express Pharma

Innovator oligonucleotide-based drugs targeting central nervous system (CNS) disorders have seen a remarkable 339 per cent increase in licensing agreement deal value, rising from $640 million in 2023 to $2.81 billion in 2024, according to GlobalData.  Oligonucleotides, which are short synthetic DNA or RNA strands, are utilised in precision medicine to selectively bind to disease-causing genetic sequences, offering targeted therapeutic options fo…

CNS innovator oligonucleotide licensing value surges by 339% to $2.8 billion in 2024, reveals GlobalData

Innovator oligonucleotide-based drugs targeting central nervous system (CNS) disorders have seen a remarkable 339% increase in licensing agreement deal value, rising from $640 million in 2023 to $2.81 billion in 2024, according to GlobalData, a leading data and analytics company. Oligonucleotides, which are short synthetic DNA or RNA strands, are utilized in precision medicine to selectively bind to disease-causing genetic sequences, offering ta…